medsovetМедицинский СоветMeditsinskiy sovet = Medical Council2079-701X2658-5790REMEDIUM GROUP Ltd.10.21518/2079-701X-2019-19-132-136medsovet-5298Research ArticleКЛИНИЧЕСКОЕ НАБЛЮДЕНИЕCLINICAL OBSERVATIONИммунотерапия рецидивного немелкоклеточного рака легкого в первой линииImmunotherapy in first-line treatment of recurrent non-small cell lung cancerhttps://orcid.org/0000-0003-4980-8986РодионовЕ. О.RodionovE. O.

 к.м.н., старший научный сотрудник отделения торакальной онкологии; ассистент кафедры онкологии,

SPIN-код: 7650-2129, AuthorID: 805452, ResearcherID: B-7280-2017, SCOPUS: 57189622130

634028, Россия, Томск, ул. Савиных, д. 12/1

634050, Россия, Томск, Московский тракт, д. 2

Cand. of Sci. (Med), Senior Researcher of the Department of Thoracic Oncology, Research Institute of Oncology; Assistant at the Department of Oncology 

SPIN-сode: 7650-2129, AuthorID: 805452, ResearcherID: B-7280-2017, SCOPUS: 57189622130

12/1, Savinykh st. Tomsk, 634028, Russia

2, Moskovskiy Hwy., Tomsk, 634050, Russia

rodionov_eo@oncology.tomsk.ruhttps://orcid.org/0000-0002-5365-9840МиллерС. В.MillerS. V.

д.м.н., ведущий научный сотрудник отделения торакальной онкологии

SPIN-код: 6510-9849, AuthorID: 558789, ResearcherID: C-8970-2012, SCOPUS: 56525429400 

634028, Россия, Томск, ул. Савиных, д. 12/1

Dr. of Sci. (Med), Head Researcher of the Department of Thoracic Oncology

SPIN-code: 6510-9849, AuthorID: 558789, ResearcherID: C-8970-2012, SCOPUS: 56525429400

12/1, Savinykh st. Tomsk, 634028, Russia

miller_sv@sibmail.comhttps://orcid.org/0000-0002-0884-1838ТузиковС. А.TuzikovS. A.

 д.м.н., заведующий отделением торакальной онкологии; профессор кафедры онкологии

SPIN-код: 5662-6431, AuthorID: 455003, ResearcherID: D-1176-2012, SCOPUS: 6507842873

634028, Россия, Томск, ул. Савиных, д. 12/1

634050, Россия, Томск, Московский тракт, д. 2

 

Dr. of Sci. (Med), Head of the Department of Thoracic Oncology, Professor of the Department of Oncology

12/1, Savinykh st. Tomsk, 634028, Russia

2, Moskovskiy Hwy., Tomsk, 634050, Russia; 

SPIN-code: 5662-6431, AuthorID: 455003, ResearcherID: D-1176-2012, SCOPUS: 6507842873

TuzikovSA@oncology.tomsk.ruhttps://orcid.org/0000-0002-9054-0742ЕфтеевЛ. А.EfteevL. A.

младший научный сотрудник отделения торакальной онкологии 

634028, Россия, Томск, ул. Савиных, д. 12/1

SPIN-код: 3474-4654, AuthorID: 978000

Junior Researcher of the Department of Thoracic Oncology

12/1, Savinykh st. Tomsk, 634028, Russia

 SPIN-code: 3474-4654, AuthorID: 978000

efteyco@rambler.ruhttps://orcid.org/0000-0002-7599-1211МарковичВ. А.MarkovichV. A.

младший научный сотрудник отделения торакальной онкологии 634028, Россия, Томск, ул. Савиных, д. 12/1

SPIN-код: 2954-8330, AuthorID: 968514

Junior Researcher of the Department of Thoracic Oncology

12/1, Savinykh st. Tomsk, 634028, Russia;

SPIN-code: 2954-8330, AuthorID: 968514

vitalii.markovich.87@mail.ruhttps://orcid.org/0000-0001-6015-7032МиллерД. С.MillerD. S.

студентка 4-го курса лечебного факультета

634050, Россия, Томск, Московский тракт, д. 2

SPIN: 3384-4789

4th year medical student

2, Moskovskiy Hwy., Tomsk, 634050, Russia

SPIN: 3384-4789

Научно-исследовательский институт онкологии, Томский национальный исследовательский медицинский центр Российской академии наук; Сибирский государственный медицинский университетРоссияFederal State Budgetary Scientific Institution «Tomsk National Research Medical Center» of the Russian Academy of Sciences;Russian FederationНаучно-исследовательский институт онкологии, Томский национальный исследовательский медицинский центр Российской академии наукРоссияResearch Institute of Oncology, Federal State Budgetary Scientific Institution «Tomsk National Research Medical Center» of the Russian Academy of SciencesRussian FederationНаучно-исследовательский институт онкологии, Томский национальный исследовательский медицинский центр Российской академии наук; Сибирский государственный медицинский университетРоссияResearch Institute of Oncology, Federal State Budgetary Scientific Institution «Tomsk National Research Medical Center» of the Russian Academy of Sciences; Federal State Budgetary Educational Institution of Higher Education «Siberian State Medical University» of the Ministry of Health of the Russian FederationRussian FederationНаучно-исследовательский институт онкологии, Томский национальный исследовательский медицинский центр Российской академии наукРоссияResearch Institute of Oncology, Federal State Budgetary Scientific Institution «Tomsk National Research Medical Center» of the Russian Academy of SciencesRussian FederationСибирский государственный медицинский университетРоссияFederal State Budgetary Educational Institution of Higher Education «Siberian State Medical University» of the Ministry of Health of the Russian FederationRussian Federation201907122019019132136Copyright © Родионов Е.О., Миллер С.В., Тузиков С.А., Ефтеев Л.А., Маркович В.А., Миллер Д.С., 20192019Родионов Е.О., Миллер С.В., Тузиков С.А., Ефтеев Л.А., Маркович В.А., Миллер Д.С.Rodionov E.O., Miller S.V., Tuzikov S.A., Efteev L.A., Markovich V.A., Miller D.S.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-sovet.pro/jour/article/view/5298иммунотерапияпембролизумабнемелкоклеточный рак легкогоаутоиммунный гипотиреозimmunotherapypembrolizumabnon-small-cell lung cancerautoimmune hypothyroidismReferencesЦыганов М.М., Родионов Е.О., Дерюшева И.В., Миллер С.В., Ибрагимова М.К., Писарева Л.Ф. и др. Оценка прогностической значимости экспрессии генов монорезистентности в опухоли больных немелкоклеточным раком легкого после предоперационной химиотерапии. Вопросы онкологии. 2017;63(1):122–125. Режим доступа: https://voprosyonkologii.ru/index.php/journal/article/view/349/349.Tsyganov M.M., Rodionov E.O., Deryusheva I.V., Miller S.V., Ibragimova M.K., Pisareva L.F. et al. Prognostic significance of monoresistance gene expression in the tumors of patients with non-small cell lung cancer after preoperative chemotherapy. Voprosy onkologii = Problems in oncology. 2017;63(1):122–5. (in Russ.) Available at: https://voprosyonkologii.ru/index.php/journal/article/view/349/349.Rodionov E.O., Miller S.V., Tuzikov S.A., et al. 1370PThe results of treatment of non-small cell lung cancer stage III with a preoperative vinorelbine/carboplatin and personalized adjuvant chemotherapy. Ann Oncol. 2018;29(8):viii490. doi: 10.1093/annonc/mdy291.007.Rodionov E.O., Miller S.V., Tuzikov S.A., et al. 1370PThe results of treatment of non-small cell lung cancer stage III with a preoperative vinorelbine/carboplatin and personalized adjuvant chemotherapy. Ann Oncol. 2018;29(8):viii490. doi: 10.1093/annonc/mdy291.007.Postmus P.E., Kerr K.M., Oudkerk M., Senan S., Waller D.A., Vansteenkiste J. et al. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(4):iv1–iv21. doi: 10.1093/annonc/mdx222.Postmus P.E., Kerr K.M., Oudkerk M., Senan S., Waller D.A., Vansteenkiste J. et al. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(4):iv1–iv21. doi: 10.1093/annonc/mdx222.Leventakos K., Mansfield A.S. Advances in the Treatment of Non–small Cell Lung Cancer: Focus on Nivolumab, Pembrolizumab, and Atezolizumab. BioDrugs. 2016;30(5):397-405. doi: 10.1007/s40259-016-0187-0.Leventakos K., Mansfield A.S. Advances in the Treatment of Non–small Cell Lung Cancer: Focus on Nivolumab, Pembrolizumab, and Atezolizumab. BioDrugs. 2016;30(5):397-405. doi: 10.1007/s40259-016-0187-0.Sul J., Blumenthal G.M., Jiang X., He K., Keegan P., Pazdur R. FDA Approval Summary: Pembrolizumab for the Treatment of Patients With Metastatic Non-Small Cell Lung Cancer Whose Tumors Express Programmed DeathLigand 1. Oncologist. 2016;21(5):643-650. doi: 10.1634/theoncologist.2015-0498.Sul J., Blumenthal G.M., Jiang X., He K., Keegan P., Pazdur R. FDA Approval Summary: Pembrolizumab for the Treatment of Patients With Metastatic Non-Small Cell Lung Cancer Whose Tumors Express Programmed DeathLigand 1. Oncologist. 2016;21(5):643-650. doi: 10.1634/theoncologist.2015-0498.Schiller J.H., Harrington D., Belani C.P., et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002;(346):92-98. doi: 10.1056/NEJMoa011954.Schiller J.H., Harrington D., Belani C.P., et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002;(346):92-98. doi: 10.1056/NEJMoa011954.Hanna N., Shepherd F.A., Fossella F.V., et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol. 2004;(22):1589-1597. doi: 10.1200/JCO.2004.08.163.Hanna N., Shepherd F.A., Fossella F.V., et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol. 2004;(22):1589-1597. doi: 10.1200/JCO.2004.08.163.Shepherd F.A., Dancey J., Ramlau R. et al. Prospective randomized trial of docetaxel versus best supportive care in patients with nonsmall-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol. 2000;18(10):2095-2103. doi: 10.1200/JCO.2000.18.10.2095.Shepherd F.A., Dancey J., Ramlau R. et al. Prospective randomized trial of docetaxel versus best supportive care in patients with nonsmall-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol. 2000;18(10):2095-2103. doi: 10.1200/JCO.2000.18.10.2095.Shepherd F.A., Rodrigues Pereira J., Ciuleanu T., et al. Erlotinib in previously treated non-smallcell lung cancer. N Engl J Med. 2005;353(2):123-132. doi: 10.1056/NEJMoa050753.Shepherd F.A., Rodrigues Pereira J., Ciuleanu T., et al. Erlotinib in previously treated non-smallcell lung cancer. N Engl J Med. 2005;353(2):123-132. doi: 10.1056/NEJMoa050753.Herbst R.S., Baas P., Kim D.-W., Felip E., PérezGracia J.L., Han J.-Y. et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016;387(10027):1540–1550. doi: 10.1016/S0140-6736(15)01281-7.Herbst R.S., Baas P., Kim D.-W., Felip E., PérezGracia J.L., Han J.-Y. et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016;387(10027):1540–1550. doi: 10.1016/S0140-6736(15)01281-7.Chatterjee M., Turner D.C., Felip E., Lena H., Cappuzzo F., Horn L. et al. Systematic evaluation of pembrolizumab dosing in patients with advanced non-small-cell lung cancer. Ann Oncol. 2016;27(7):1291–1298. doi: 10.1093/annonc/mdw174.Chatterjee M., Turner D.C., Felip E., Lena H., Cappuzzo F., Horn L. et al. Systematic evaluation of pembrolizumab dosing in patients with advanced non-small-cell lung cancer. Ann Oncol. 2016;27(7):1291–1298. doi: 10.1093/annonc/mdw174.Reck M., Rodríguez-Abreu D., Robinson A.G., Hui R., Csőszi T., Fülöp A. et al. Pembrolizumab versus сhemotherapy for PD-L1–positive non–small cell lung cancer. N Engl J Med. 2016;375(19):1823-1833. doi: 10.1056/NEJMoa1606774.Reck M., Rodríguez-Abreu D., Robinson A.G., Hui R., Csőszi T., Fülöp A. et al. Pembrolizumab versus сhemotherapy for PD-L1–positive non–small cell lung cancer. N Engl J Med. 2016;375(19):1823-1833. doi: 10.1056/NEJMoa1606774.Reck A.M., Rodrigues-Abreu D., Robinson A.G., Hui R., et al. Updated analysis of KEYNOTE-024: Pembrolizumab versus platinum-based chemotherapy for advanced non – small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater. J Clin Oncol. 2019;37(7):537-546. doi: 10.1200/JCO.18.00149.Reck A.M., Rodrigues-Abreu D., Robinson A.G., Hui R., et al. Updated analysis of KEYNOTE-024: Pembrolizumab versus platinum-based chemotherapy for advanced non – small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater. J Clin Oncol. 2019;37(7):537-546. doi: 10.1200/JCO.18.00149.Qin A., Street L., Cease K., Viglianti B., Warren E. et al. Clinical Determinants of Durable Clinical Benefit of Pembrolizumab in Veterans With Advanced Non-Small-Cell Lung Cancer. Clin Lung Cancer. 2017;18(5):559-564. doi: 10.1016/j.cllc.2017.01.012.Qin A., Street L., Cease K., Viglianti B., Warren E. et al. Clinical Determinants of Durable Clinical Benefit of Pembrolizumab in Veterans With Advanced Non-Small-Cell Lung Cancer. Clin Lung Cancer. 2017;18(5):559-564. doi: 10.1016/j.cllc.2017.01.012.

The authors declare that there are no conflicts of interest present.